Lisal Folsom, MD
Pediatric Endocrinology · Louisville, KYNPI 1215165675
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,626 of the $16,390 with a category attached, or 64.8%. Sanofi-aventis U.S. LLC accounts for 74.8% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $5,686, 8.3 times the $683 reported in 2019.
Across 58 payments — averaging $282.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- Medtronic$691
- Novo Nordisk$684
- Insulet Corporation$576
- BETA Bionics, Inc.$291
- Abbott$233
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$10,62665%
- Travel & lodging$6404%
- Food & beverage$5,10931%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 14 | $12,255 |
| Medtronic(2 entities) | 9 | $691 |
| Novo Nordisk | 8 | $684 |
| Insulet Corporation | 5 | $576 |
| BETA Bionics, Inc. | 3 | $291 |
| Abbott | 2 | $233 |
| Amryt Pharma Holdings Ltd | 2 | $222 |
| Tandem Diabetes Care, Inc. | 2 | $171 |
| Radius Health, Inc. | 2 | $137 |
| Neurocrine Biosciences, Inc. | 1 | $131 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Amgen | 1 | $121 |
| Soleno Therapeutics, Inc. | 1 | $120 |
| Ultragenyx Pharmaceutical Inc. | 1 | $120 |
| Lilly USA, LLC | 1 | $114 |
| Shire North American Group Inc | 1 | $112 |
| Dexcom, Inc. | 1 | $74 |
| Xeris Pharmaceuticals, Inc. | 1 | $67 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$654
- TZIELD$642
- Omnipod$576
- MINIMED 780G$262
- iLet Insulin Infusion Kit Inset$218
- iLet Insulin Infusion Kit Contact Detach$218
- MYCAPSSA$139
- CRENESSITY$131
- NEXLIZET$125
- NEXLETOL$125
- Yorvipath$125
- FreeStyle Libre$124
- Tymlos$123
- TEPEZZA$121
- VYKAT XR$120
- CRYSVITA$120
- Ozempic$120
- MOUNJARO$114
- Minimed 670G System$109
- FREESTYLE LIBRE 3$109
How this compares
Too few pediatric endocrinology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 37 | $36,125 |
| JardianceEmpagliflozin | 30 | $30,307 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $24,231 |
| GenotropinSomatropin | 11 | $19,188 |
| OzempicSemaglutide | 13 | $16,294 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $11,679 |
| Levothyroxine Sodium | 130 | $1,244 |
| Testosterone Cypionate | 24 | $926 |
| SynthroidLevothyroxine Sodium | 11 | $277 |
| Estradiol | 11 | $233 |
| Metformin Hcl ErMetformin Hcl | 14 | $148 |
| Atorvastatin Calcium | 29 | $121 |
| Methimazole | 13 | $97 |
| Alendronate Sodium | 20 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $114 | $36,12537 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $12,255 | $24,23116 claims |
| PfizerGenotropin | $20 | $19,18811 claims |
| Novo NordiskOzempic | $684 | $16,29413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric endocrinology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other pediatric endocrinology in Louisville
- Kupper WintergerstLouisville$313K
- Catalina Cabrera-SalcedoLouisville$1K
- Susan RaghavanLouisville$864
- Bradly ThrasherLouisville$478
- Michael FosterLouisville$337
- Sara WatsonLouisville$249
- Adetokunbo OmoruyiLouisville$114
- Megan CoriellLouisville$100
- Aurelia WoodLouisville$13
- Sarah SwaugerLexington$371
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.